<div id="readability-page-1">CeriBell NASDAQ: CBLL outlined its recent progress and 2026 priorities at a JPMorgan MedTech event, emphasizing continued growth in acute-care seizure detection and an expanding roadmap for additional EEG-based indications, including delirium and stroke monitoring.<h2>Platform overview and 2025 accomplishments</h2> Chief Executive Officer Jane Chao said the company has built a neuromonitoring platform designed to make EEG acquisition faster and easier in acute-care settings. The system uses a disposable headband connected to a phone-sized recorder that can display information at the bedside and stream data to a cloud portal for physician review. Chao highlighted the company’s AI-powered algorithm, Clarity, which continuously analyzes EEG data and is designed to detect multiple neurological disorders. To date, the company’s commercial efforts have been “100% focused” on seizure detection in acute care settings, primarily the ICU and emergency department. For 2025, Chao said the company is guiding revenue of $87 million to $89 million, representing 34% year-over-year growth with 88% gross margin. She also said the company expanded its total addressable market (TAM) in 2025, growing it from $2 billion to $3.5 billion, driven by pediatric and neonatal expansion as well as FDA clearance for delirium detection. <h2>Why Ceribell targets ICU and ED seizure detection</h2> Chao described seizures in the ICU as common and frequently non-convulsive, stating that 92% of ICU seizures are non-convulsive and therefore require EEG for diagnosis. She argued that seizures in critical care can also be prolonged and more severe, with patients potentially seizing for hours to days. She emphasized the importance of early detection and treatment, noting that if treatment occurs within the first 30 minutes of seizure onset, 80% of patients respond, but delaying treatment by one to two hours can cut response rates roughly in half. Chao argued that conventional EEG workflows create delays due to staffing and interpretation bottlenecks, including reliance on EEG technicians for setup and specialized neurologists for interpretation. She said that even where conventional EEG is available, continuous monitoring is challenging due to the time involved in reviewing long recordings. <h2>Product workflow, Clarity features, and clinical evidence cited</h2> Chao said Ceribell’s system is designed so bedside staff can initiate EEG in about five minutes. Clarity then analyzes EEG in 10-second intervals and provides outputs such as seizure burden, which she described as a metric recommended by the American Neurophysiology Society. She said the system can generate alerts when seizure burden approaches status epilepticus. Chao walked through a community hospital case example described as occurring at 1:00 a.m., where the device alerted clinicians to status epilepticus and helped guide treatment escalation as seizure burden changed over time. She said the case illustrated the importance of continuous monitoring, including the ability to detect seizure recurrence after an earlier resolution. She also cited published evidence supporting the platform, including what she described as the company’s largest study to date, the SAFER study, a retrospective analysis of about 1,000 patients conducted at Yale, University of New Mexico, and Mass General. Chao said the study found conventional EEG arrived at the bedside 19 hours later even at top teaching centers, while Ceribell use was associated with: <ul> <li>4.1 days shorter ICU length of stay</li> <li>A reduction in severe disability at discharge from 76% (conventional cohort) to 58% (Ceribell cohort)</li> </ul> <h2>Business model, penetration, and 2026 growth priorities</h2> Chao described a recurring-revenue model consisting of subscription fees (about 25% of revenue) for access to recorders, Clarity, and the portal, and disposable single-patient headbands (about 75% of revenue). She said quarterly revenue has increased sequentially throughout the company’s commercial history. She estimated Ceribell is about 3% penetrated in the U.S. acute-care seizure market, based on being in 600+ hospitals out of 6,000 and serving about 30% of addressable patients within existing customer hospitals. For 2026, Chao outlined catalysts on both account acquisition and utilization: <ul> <li>Sales force expansion completed in 2025, with expected productivity in 2026</li> <li>FedRAMP High cybersecurity certification, which she said enables access to ~160 VA hospitals; she noted a completed VA pilot and early cohort wins</li> <li>Utilization initiatives including departmental expansion within hospitals, broader training, and integration into patient protocols (e.g., post-stroke, post-cardiac arrest)</li> </ul> Chao also said Ceribell received FDA clearance for Clarity in neonatal and pediatric populations, including preterm neonates through age one and pediatric patients age one and older. She said this expands TAM by about $400 million and opens access to 280 children’s hospitals, with a full launch planned in 2026 following a limited commercial pilot. <h2>Delirium and the “EEG as a new vital sign” vision</h2> Chao framed the company’s longer-term strategy in three horizons: (1) continued penetration of seizure detection in acute care, (2) expansion within acute care beyond seizures to indications such as delirium and stroke, and (3) potential expansion beyond acute care into outpatient settings and broader neurological or psychiatric applications. She said 2025 was a milestone year for the second horizon, highlighting FDA clearance for delirium detection, which she described as the first and only FDA-cleared delirium detection tool. She also said Ceribell submitted an NTAP application based on an existing breakthrough designation, which she said unlocks at least a $1 billion opportunity in the ICU, and received a breakthrough designation for large vessel occlusion monitoring in the inpatient setting. Chao characterized delirium as “acute brain failure” and said it is common in the ICU, affecting 3+ million patients, with prevalence of ~30% in ICU patients and up to 80% in ventilated patients. She criticized the current CAM-ICU behavioral assessment as subjective, binary, and not continuous, arguing that delirium waxes and wanes and would benefit from objective trending. She also emphasized the clinical overlap between seizure and delirium, noting that benzodiazepines are first-line for seizures but are “the number one deliriogenic agent,” making differentiation important. She cited statistics that 48% of seizure patients later experience delirium and 42% of delirious patients have seizure or seizure-like abnormalities. During Q&amp;A, Chao said delirium is expected to be more impactful in 2027 and beyond. She said Ceribell plans to conduct market development and a commercial pilot in 2026, with a full delirium launch planned for Q4 2026 or early 2027, and expects to largely leverage its existing sales force because the call points overlap with current customers. On profitability, Chao said the company is “growth first, but not growth at all cost” and expressed confidence it can reach break-even with cash raised during its IPO, though she did not provide a specific timeline.<h2>About CeriBell NASDAQ: CBLL</h2>CeriBell Corp NASDAQ: CBLL is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention. The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.<h2>Read More</h2><ul><li>Five stocks we like better than CeriBell</li><li>This $15 Stock Could Go Down as the #1 Stock of 2026</li><li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li><li>Punch these codes into your ordinary brokerage account</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li><li>Bitcoin grabs headlines, but smart money likes this token</li></ul>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in CeriBell Right Now?</h2>Before you consider CeriBell, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.While CeriBell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

CeriBell (NASDAQ:CBLL) presented its growth strategy for 2026 at the JPMorgan MedTech event, focusing on acute-care seizure detection and expanding EEG applications for delirium and stroke monitoring. CEO Jane Chao highlighted the company's AI-driven neuromonitoring platform, which aims to streamline EEG acquisition in critical care. CeriBell anticipates revenue growth of 34% in 2025, with a total addressable market increase from $2 billion to $3.5 billion. The company plans to enhance its market penetration and has received FDA clearance for pediatric and neonatal EEG applications, targeting a full launch in 2026.

CeriBell Maps 2026 Growth at JPMorgan MedTech, Eyes Delirium and Stroke EEG Expansion